New drug may tame immunotherapy skin rash and keep cancer treatment on track
Symptom relief
Recruiting now
This study tests a JAK inhibitor drug (upadacitinib) for cancer patients who develop a severe skin rash from immunotherapy. The goal is to quickly relieve the rash without using steroids, which can weaken the cancer treatment. About 35 adults with solid tumors and grade 3-4 rash …
Phase: PHASE2 • Sponsor: Shixiu Wu • Aim: Symptom relief
Last updated May 01, 2026 15:59 UTC